These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 24291018)
1. Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and -4 in active Crohn's disease. Schmid W; Vogelsang H; Papay P; Primas C; Eser A; Gratzer C; Handler M; Novacek G; Panzer S J Crohns Colitis; 2014 Jun; 8(6):495-503. PubMed ID: 24291018 [TBL] [Abstract][Full Text] [Related]
2. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition. Badr Eslam R; Lang IM; Kaider A; Panzer S Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628 [TBL] [Abstract][Full Text] [Related]
3. Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. Badr Eslam R; Lang IM; Koppensteiner R; Calatzis A; Panzer S; Gremmel T Int J Cardiol; 2013 Sep; 168(1):403-6. PubMed ID: 23041015 [TBL] [Abstract][Full Text] [Related]
4. Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin. Ofosu FA Transfus Apher Sci; 2003 Jun; 28(3):265-8. PubMed ID: 12725953 [TBL] [Abstract][Full Text] [Related]
5. Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. Quinton TM; Kim S; Derian CK; Jin J; Kunapuli SP J Biol Chem; 2004 Apr; 279(18):18434-9. PubMed ID: 14973136 [TBL] [Abstract][Full Text] [Related]
6. Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease. Gremmel T; Koppensteiner R; Ay C; Panzer S Eur J Clin Invest; 2014; 44(3):319-24. PubMed ID: 24382127 [TBL] [Abstract][Full Text] [Related]
7. Coordinate activation of human platelet protease-activated receptor-1 and -4 in response to subnanomolar alpha-thrombin. Ofosu FA; Dewar L; Craven SJ; Song Y; Cedrone A; Freedman J; Fenton JW J Biol Chem; 2008 Oct; 283(40):26886-93. PubMed ID: 18682394 [TBL] [Abstract][Full Text] [Related]
8. Differential involvement of thrombin receptors in Ca2+ release from two different intracellular stores in human platelets. Jardin I; Ben Amor N; Bartegi A; Pariente JA; Salido GM; Rosado JA Biochem J; 2007 Jan; 401(1):167-74. PubMed ID: 16939417 [TBL] [Abstract][Full Text] [Related]
9. Early intraplatelet signaling enhances the release of human platelet PAR-1 and -4 amino-terminal peptides in response to thrombin. Ofosu FA; Dewar L; Song Y; Cedrone AC; Hortelano G; Craven SJ Biochemistry; 2009 Feb; 48(7):1562-72. PubMed ID: 19182900 [TBL] [Abstract][Full Text] [Related]
10. Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance. Gnanenthiran SR; Pennings GJ; Reddel CJ; Campbell H; Kockx M; Hamilton JR; Chen VM; Kritharides L Arterioscler Thromb Vasc Biol; 2022 Aug; 42(8):960-972. PubMed ID: 35708029 [TBL] [Abstract][Full Text] [Related]
11. PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. Henriksen RA; Hanks VK Arterioscler Thromb Vasc Biol; 2002 May; 22(5):861-6. PubMed ID: 12006403 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of proteinase-activated receptor agonists on human platelets. Chung AW; Jurasz P; Hollenberg MD; Radomski MW Br J Pharmacol; 2002 Mar; 135(5):1123-32. PubMed ID: 11877318 [TBL] [Abstract][Full Text] [Related]
13. Different Effects of Ranibizumab and Bevacizumab on Platelet Activation Profile. Sobolewska B; Grimmel C; Gatsiou A; Sopova K; Klein J; Biedermann T; Stellos K; Ziemssen F Ophthalmologica; 2015; 234(4):195-210. PubMed ID: 26305017 [TBL] [Abstract][Full Text] [Related]
14. Thrombin is a selective inducer of heparanase release from platelets and granulocytes via protease-activated receptor-1. Tatour M; Shapira M; Axelman E; Ghanem S; Keren-Politansky A; Bonstein L; Brenner B; Nadir Y Thromb Haemost; 2017 Jun; 117(7):1391-1401. PubMed ID: 28569922 [TBL] [Abstract][Full Text] [Related]
15. C1-inhibitor influence on platelet activation by thrombin receptors agonists. Tarandovskiy ID; Buehler PW; Karnaukhova E Clin Appl Thromb Hemost; 2022; 28():10760296221120422. PubMed ID: 35996317 [TBL] [Abstract][Full Text] [Related]
16. Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand. Moschonas IC; Kellici TF; Mavromoustakos T; Stathopoulos P; Tsikaris V; Magafa V; Tzakos AG; Tselepis AD Platelets; 2017 Dec; 28(8):812-821. PubMed ID: 28267389 [TBL] [Abstract][Full Text] [Related]
17. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW Transl Res; 2013 May; 161(5):421-9. PubMed ID: 23340049 [TBL] [Abstract][Full Text] [Related]
18. Impact of diabetes on platelet activation in different manifestations of atherosclerosis. Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S Swiss Med Wkly; 2013; 143():w13800. PubMed ID: 23740526 [TBL] [Abstract][Full Text] [Related]
20. Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans. Gudmundsdóttir IJ; Megson IL; Kell JS; Ludlam CA; Fox KA; Webb DJ; Newby DE Circulation; 2006 Oct; 114(15):1625-32. PubMed ID: 17015787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]